DA Davidson analyst Linda Bolton Weiser kept her Buy rating and $249 price target on Medifast after the company's ICR presentation, saying its break-out sessions were also "very well attended". The analyst notes that "many investors" are looking into the company with a no debt on its balance sheet with a 56% recent dividend increase trading at an attractive valuation of 14.5-times her expected forward earnings. Weiser adds that Medifast also affirmed its FY18 outlook and offered a long term revenue growth view of 25%, which is in line with her "thinking". The analyst contends that the shares present an "excellent entry point" after the stock price came in from over $250 for reasons that are not fundamental.